| 9.18 -0.06 (-0.65%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.37 | 1-year : | 13.28 |
| Resists | First : | 9.73 | Second : | 11.37 |
| Pivot price | 9.2  |
|||
| Supports | First : | 8.6 | Second : | 7.9 |
| MAs | MA(5) : | 9.33 |
MA(20) : | 9.04 |
| MA(100) : | 8.95 |
MA(250) : | 10.23 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 59 |
D(3) : | 70 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 14.51 | Low : | 6.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARVN ] has closed above bottom band by 47.5%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.25 - 9.33 | 9.33 - 9.38 |
| Low: | 8.86 - 8.95 | 8.95 - 9 |
| Close: | 9.07 - 9.2 | 9.2 - 9.29 |
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Fri, 28 Aug 2026
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Fri, 14 Aug 2026
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Sat, 08 Aug 2026
Precision Trading with Arvinas Inc. (ARVN) Risk Zones - Stock Traders Daily
Thu, 06 Aug 2026
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Tue, 04 Aug 2026
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Tue, 04 Aug 2026
ARVINAS ($ARVN) Releases Q2 2026 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5.681e+007 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 4,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.9e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2.9 % |
| Operating Margin | 66.3 % |
| Return on Assets (ttm) | -1.1 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 8.44 |
| Sales Per Share | 1.82011e+008 |
| EBITDA (p.s.) | 1.76839e+008 |
| Qtrly Earnings Growth | 0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -207 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.85 |
| Dividend | 0 |
| Forward Dividend | 4e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|